MX2018013956A - Virus pichinde de tres segmentos como vectores de vacunas. - Google Patents
Virus pichinde de tres segmentos como vectores de vacunas.Info
- Publication number
- MX2018013956A MX2018013956A MX2018013956A MX2018013956A MX2018013956A MX 2018013956 A MX2018013956 A MX 2018013956A MX 2018013956 A MX2018013956 A MX 2018013956A MX 2018013956 A MX2018013956 A MX 2018013956A MX 2018013956 A MX2018013956 A MX 2018013956A
- Authority
- MX
- Mexico
- Prior art keywords
- tri
- segment
- orf
- vaccine vectors
- pichinde virus
- Prior art date
Links
- 241000712910 Pichinde mammarenavirus Species 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000008707 rearrangement Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
- C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente solicitud se refiere a virus Pichinde con reordenamientos de sus marcos de lectura abiertos ("ORF") en sus genomas. En particular, en el presente documento se describe un segmento genómico del virus Pichinde modificado, en donde el segmento genómico del virus Pichinde es genéticamente manipulado para llevar un ORF viral en una posición diferente a la posición de tipo silvestre del ORF. En el presente documento también se describen partículas de virus Pichinde de tres segmentos que comprenden un segmento L y dos segmentos S o dos segmentos L y un segmento S. El virus Pichinde, descrito en el presente documento puede ser adecuado para vacunas y/o tratamiento de enfermedades y/o para el uso en inmunoterapias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662338400P | 2016-05-18 | 2016-05-18 | |
PCT/EP2017/061865 WO2017198726A1 (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018013956A true MX2018013956A (es) | 2019-07-04 |
Family
ID=58800799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013956A MX2018013956A (es) | 2016-05-18 | 2017-05-17 | Virus pichinde de tres segmentos como vectores de vacunas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20190135875A1 (es) |
EP (1) | EP3458593A1 (es) |
JP (2) | JP7254018B2 (es) |
KR (2) | KR102671785B1 (es) |
CN (2) | CN109804074B (es) |
AU (2) | AU2017266738B2 (es) |
BR (1) | BR112018073794A2 (es) |
CA (1) | CA3023599A1 (es) |
EA (1) | EA201892648A1 (es) |
IL (1) | IL262963A (es) |
MX (1) | MX2018013956A (es) |
SG (1) | SG11201810048VA (es) |
WO (1) | WO2017198726A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2238255T3 (da) | 2007-12-27 | 2013-11-18 | Univ Zuerich | Replikationsdefekte arenavirusvektorer |
WO2015082570A1 (en) | 2013-12-03 | 2015-06-11 | Hookipa Biotech Ag | Cmv vaccines |
WO2016075250A1 (en) | 2014-11-13 | 2016-05-19 | Université De Genève | Tri-segmented arenaviruses as vaccine vectors |
AU2016274655B2 (en) | 2015-06-10 | 2021-06-17 | Hookipa Biotech Gmbh | HPV vaccines |
AU2016348675B2 (en) | 2015-11-04 | 2022-11-17 | Hookipa Biotech Gmbh | Vaccines against Hepatitis B virus |
EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
WO2018185307A1 (en) | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
AU2020377504A1 (en) | 2019-11-07 | 2022-06-02 | Universität Basel | Arenaviruses as vectors |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
PE20240647A1 (es) | 2020-05-29 | 2024-04-04 | Hookipa Biotech Gmbh | Estrategias de tratamiento del cancer mediante el uso de vectores de arenavirus |
MX2023011054A (es) | 2021-03-23 | 2023-11-22 | Hookipa Biotech Gmbh | Arenavirus utilizados en tratamientos del cáncer de próstata. |
EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
EP4337320A1 (en) | 2021-05-13 | 2024-03-20 | Hookipa Biotech GmbH | Arenaviruses as vectors |
WO2022269362A2 (en) * | 2021-06-21 | 2022-12-29 | Vaxxinova International B.V. | Veterinary viral vector |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022381821A1 (en) | 2021-11-08 | 2024-05-23 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
DK2238255T3 (da) * | 2007-12-27 | 2013-11-18 | Univ Zuerich | Replikationsdefekte arenavirusvektorer |
US9809801B2 (en) * | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
CN103224999B (zh) * | 2013-04-25 | 2015-11-18 | 中华人民共和国大榭出入境检验检疫局 | 检测沙粒病毒科病毒的简并引物及rt-pcr检测方法 |
ES2746150T3 (es) * | 2014-09-22 | 2020-03-04 | Univ Minnesota | Sistema de genética inversa para el virus Pichindé y métodos de uso |
-
2017
- 2017-05-17 EP EP17726575.8A patent/EP3458593A1/en active Pending
- 2017-05-17 CN CN201780044797.7A patent/CN109804074B/zh active Active
- 2017-05-17 SG SG11201810048VA patent/SG11201810048VA/en unknown
- 2017-05-17 MX MX2018013956A patent/MX2018013956A/es unknown
- 2017-05-17 KR KR1020187036105A patent/KR102671785B1/ko active IP Right Grant
- 2017-05-17 JP JP2019513483A patent/JP7254018B2/ja active Active
- 2017-05-17 EA EA201892648A patent/EA201892648A1/ru unknown
- 2017-05-17 CN CN202311410316.3A patent/CN117486979A/zh active Pending
- 2017-05-17 US US16/302,086 patent/US20190135875A1/en not_active Abandoned
- 2017-05-17 AU AU2017266738A patent/AU2017266738B2/en active Active
- 2017-05-17 CA CA3023599A patent/CA3023599A1/en active Pending
- 2017-05-17 KR KR1020247018106A patent/KR20240095333A/ko unknown
- 2017-05-17 WO PCT/EP2017/061865 patent/WO2017198726A1/en unknown
- 2017-05-17 BR BR112018073794-1A patent/BR112018073794A2/pt unknown
-
2018
- 2018-11-12 IL IL262963A patent/IL262963A/en unknown
-
2022
- 2022-05-23 US US17/751,319 patent/US20220289797A1/en active Pending
- 2022-10-06 JP JP2022161464A patent/JP2023012463A/ja active Pending
-
2023
- 2023-12-18 AU AU2023285703A patent/AU2023285703A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190135875A1 (en) | 2019-05-09 |
KR102671785B1 (ko) | 2024-06-04 |
JP2019516410A (ja) | 2019-06-20 |
AU2017266738A1 (en) | 2018-11-29 |
AU2023285703A1 (en) | 2024-01-18 |
CN117486979A (zh) | 2024-02-02 |
CN109804074A (zh) | 2019-05-24 |
JP7254018B2 (ja) | 2023-04-07 |
CA3023599A1 (en) | 2017-11-23 |
US20220289797A1 (en) | 2022-09-15 |
KR20240095333A (ko) | 2024-06-25 |
CN109804074B (zh) | 2023-10-10 |
AU2017266738B2 (en) | 2023-10-12 |
JP2023012463A (ja) | 2023-01-25 |
KR20190016032A (ko) | 2019-02-15 |
EA201892648A1 (ru) | 2019-06-28 |
WO2017198726A1 (en) | 2017-11-23 |
BR112018073794A2 (pt) | 2019-02-26 |
EP3458593A1 (en) | 2019-03-27 |
IL262963A (en) | 2018-12-31 |
SG11201810048VA (en) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018013956A (es) | Virus pichinde de tres segmentos como vectores de vacunas. | |
CY1123339T1 (el) | Τρι-τμηματικοι αρεναϊοι ως φορεις εμβολιου | |
MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
MX2016004063A (es) | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. | |
MX2023008067A (es) | Virus vaccinia atenuados competentes para replicacion con delecion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer. | |
WO2015061294A8 (en) | Use of sting agonists to treat chronic hepatitis b virus infection | |
MX2021001883A (es) | Virus recombinantes del mixoma y usos de los mismos. | |
TW201612190A (en) | Flavivirus virus like particle | |
MX349294B (es) | Formulaciones virales liofilizadas. | |
MX2016013631A (es) | Celulas huespedes modificadas y usos de las mismas. | |
WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
PH12015501721A1 (en) | Porcine parvovirus 5b, methods of use and vaccine | |
IL290819A (en) | Genetically engineered oncolytic cowpox viruses and methods of using them | |
PH12020551944A1 (en) | Reverse peptide vaccine | |
HRP20201523T1 (hr) | Cjepivo | |
EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
MX354758B (es) | Metodos para la liberacion de las particulas similares a virus. | |
WO2018056528A3 (ko) | 인플루엔자 b 백신 | |
GB2547835A (en) | Protective material | |
EA202191862A3 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
MY185444A (en) | Enterovirus 71 antiviral peptides | |
Kalla et al. | ASSESSMENT OFTHE VIABILITY OF THE COCCOID FORM OF HELICOBACTER PYLORI IN MICE | |
EA201892348A1 (ru) | Комбинации и способы, включающие ингибитор сборки капсида |